21 Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) as Adjuvant Treatment in Patients (pts) With HR+/HER2– ...
Background Interim results from the phase 3 NATALEE trial showed that ribociclib added to standard-of-care adjuvant nonsteroidal aromatase inhibitor (NSAI) had a significant invasive disease-free survival (iDFS) benefit in patients with stage II/III HR …